Bisphosphonate therapy for the treatment of skeletal complications in patients with prostate cancer

Andrea L. Harzstark, Charles J. Ryan, Eric J. Small

Research output: Contribution to journalReview articlepeer-review

Abstract

Osseous metastases and osteoporotic fractures are a serious problem in patients with prostate cancer. As androgen-deprivation therapy is being used earlier in the course of the disease, the risk of osteoporosis and insufficiency fractures is increasing. In this review, the contribution of androgen-deprivation therapy to osteoporosis and bone metastases will be discussed. The role of bisphosphonates in treating osteoporosis and bone metastases will also be reviewed. The review will conclude with a discussion of the toxicities associated with bisphosphonate use.

Original languageEnglish (US)
Pages (from-to)943-954
Number of pages12
JournalAging Health
Volume2
Issue number6
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Keywords

  • Bisphosphonates
  • Bone metastasis
  • Prostate cancer
  • Skeletal complications of malignancy

Fingerprint Dive into the research topics of 'Bisphosphonate therapy for the treatment of skeletal complications in patients with prostate cancer'. Together they form a unique fingerprint.

Cite this